RT Journal Article
SR Electronic
T1 Multi-omics profiling with untargeted proteomics for blood-based early detection of lung cancer
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.01.03.24300798
DO 10.1101/2024.01.03.24300798
A1 Koh, Brian
A1 Liu, Manway
A1 Almonte, Rebecca
A1 Ariad, Daniel
A1 Bundalian, Ghristine
A1 Chan, Jessica
A1 Choi, Jinlyung
A1 Chou, Wan-Fang
A1 Cuaresma, Rea
A1 Hoedt, Esthelle
A1 Hopper, Lexie
A1 Hu, Yuntao
A1 Jain, Anisha
A1 Khaledian, Ehdieh
A1 Khin, Thidar
A1 Kokate, Ajinkya
A1 Lee, Joon-Yong
A1 Leung, Stephanie
A1 Lin, Chi-Hung
A1 Marispini, Mark
A1 Malekpour, Hoda
A1 Mora, Megan
A1 Mudaliar, Nithya
A1 Golmaei, Sara Nouri
A1 Qian, Hao
A1 Ramaiah, Madhuvanthi
A1 Ramaswamy, Saividya
A1 Ranjan, Purva
A1 Shu, Guanhua
A1 Spiro, Peter
A1 Ta, Benjamin
A1 Vitko, Dijana
A1 Waiss, Jacob
A1 Yanagihara, Zachary
A1 Zawada, Robert
A1 Zeng, Jimmy Yi
A1 Zhang, Susan
A1 Yee, James
A1 Blume, John E.
A1 Belthangady, Chinmay
A1 Wilcox, Bruce
A1 Ma, Philip
YR 2024
UL http://medrxiv.org/content/early/2024/01/04/2024.01.03.24300798.abstract
AB Blood-based approaches to detect early-stage cancer provide an opportunity to improve survival rates for lung cancer, the most lethal cancer world-wide. Multiple approaches for blood-based cancer detection using molecular analytes derived from individual ‘omics (cell-free DNA, RNA transcripts, proteins, metabolites) have been developed and tested, generally showing significantly lower sensitivity for early-stage versus late-stage cancer. We hypothesized that an approach using multiple types of molecular analytes, including broad and untargeted coverage of proteins, could identify biomarkers that more directly reveal changes in gene expression and molecular phenotype in response to carcinogenesis to potentially improve detection of early-stage lung cancer. To that end, we designed and conducted one of the largest multi-omics, observational studies to date, enrolling 2513 case and control subjects. Multi-omics profiling detected 113,671 peptides corresponding to 8385 protein groups, 219,729 RNA transcripts, 71,756 RNA introns, and 1801 metabolites across all subject samples. We then developed a machine learning-based classifier for lung cancer detection comprising 682 of these multi-omics analytes. This multi-omics classifier demonstrated 89%, 80%, and 98-100% sensitivity for all-stage, stage I, and stage III-IV lung cancer, respectively, at 89% specificity in a validation set. The application of a multi-omics platform for discovery of blood-based disease biomarkers, including proteins and complementary molecular analytes, enables the noninvasive detection of early-stage lung cancer with the potential for downstaging at initial diagnosis and the improvement of clinical outcomes.Competing Interest StatementAll authors are current or former employees and shareholders of PrognomiQ and have declared no other conflicts of interest.Funding StatementThis work was supported by PrognomiQ. PrognomiQ was involved in the study design, study execution, analysis and interpretation (no grant number)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Western Institutional Review Board (WIRB) of WCG gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data referenced in this study will be made available upon reasonable written request and following submission to all study institutional review boards and approval at all participating sites